Compare UTF & LGND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UTF | LGND |
|---|---|---|
| Founded | N/A | 1987 |
| Country | United States | United States |
| Employees | N/A | 68 |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 3.7B |
| IPO Year | 2004 | N/A |
| Metric | UTF | LGND |
|---|---|---|
| Price | $28.00 | $299.86 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $256.29 |
| AVG Volume (30 Days) | 241.9K | ★ 354.1K |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $1.25 |
| Revenue Next Year | N/A | $19.41 |
| P/E Ratio | ★ N/A | $76.27 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $23.42 | $131.67 |
| 52 Week High | $28.11 | $326.63 |
| Indicator | UTF | LGND |
|---|---|---|
| Relative Strength Index (RSI) | 62.65 | 54.03 |
| Support Level | $26.54 | $290.20 |
| Resistance Level | $28.11 | $326.63 |
| Average True Range (ATR) | 0.29 | 10.96 |
| MACD | 0.00 | -3.74 |
| Stochastic Oscillator | 82.89 | 24.94 |
Cohen & Steers Infrastructure Fund Inc is a diversified, closed-end management investment company. Its primary investment objective is total return with an emphasis on income. Under normal market conditions, the fund invests the majority of its managed assets in securities issued by infrastructure companies, which consist of utilities, pipelines, toll roads, airports, railroads, ports, telecommunications companies, and other infrastructure companies.
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.